Medios AG Appoints Stefan Bauerreis as New CFO to Drive Specialty Pharma Growth

Medios AG, Germany's first listed specialty pharmaceutical company and a leading provider of Specialty Pharma in Europe, has announced a significant leadership transition with the appointment of Stefan Bauerreis as its new Chief Financial Officer (CFO) and member of the Executive Board, effective April 15, 2026. Bauerreis succeeds Falk Neukirch, who will step down at his own request at the end of his regular term on April 30, 2026. This strategic move brings an experienced finance expert with extensive international leadership background to Medios, as Bauerreis previously served as CFO of the Stabilus Group and held various senior finance roles within the Schaeffler Group for over two decades, including CFO positions for the Europe region and Germany. His expertise spans Corporate Accounting, Controlling, Financing, and the transformation and management of international companies, positioning him well to contribute to Medios' growth trajectory.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized that Bauerreis is a proven financial expert with extensive experience in internationally positioned SDAX and MDAX companies, combining operational excellence with strategic foresight. Samson expressed confidence that Bauerreis will provide important momentum for the future development of Medios, particularly in leading the company through periods of transformation. Bauerreis himself expressed enthusiasm for his new role, stating he looks forward to helping shape the future of Medios AG as part of the Executive Board and contributing to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company both nationally and internationally, in the best interest of shareholders and employees.

The announcement also highlights important events for the Medios Group in the 2026 financial year, including investor conferences like the Metzler Small Cap Days 2026 in Frankfurt and TP ICAP Midcap Conference 2026 in Paris, along with key financial reporting dates such as the Quarterly Statement as of March 31, 2026, Annual General Meeting 2026, Half-Year Financial Report 2026, Medios Capital Markets Day, and Quarterly Statement as of September 30, 2026. Medios AG, with locations in Germany, the Netherlands, Belgium and Spain, focuses on pioneering individualized medicine to make innovative therapies available through partnerships with pharmacies, specialist practices and pharmaceutical companies. The company's shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. For more information, visit www.medios.group and explore details about individualized medicine at their dedicated platform. The original release can be viewed on www.newmediawire.com.